Table of Contents

HK J Paediatr (New Series)
Vol 17. No. 3, 2012

HK J Paediatr (New Series) 2012;17:179-182

Case Report

Retroperitoneal Inflammatory Myofibroblastic Tumour in Children: A Case Report and Review of Literature

JH Zhan, XR Luo, ZW Guan, XL Hu, Y Liu, GQ Bao


Inflammatory myofibroblastic tumour (IMT) is a kind of rare soft tissue tumour. The most commonly affected organ reported is the lung. However, IMT can occur in any organ of the body. Although abdominal IMTs have been reported, retroperitoneal tumours are exceedingly rare. We here present a case of a thirteen-year old boy with a huge retroperitoneal mass diagnosed as IMT. The tumor was excised completely and no recurrence was found one year after surgery.

Keyword : Inflammatory myofibroblastic tumour; Retroperitoneal; Surgery

Abstract in Chinese


Inflammatory myofibroblastic tumour (IMT) occurs commonly in the lung. Extra-pulmonary IMT in children have been described of its present in the mesentery, omentum, liver, bladder, mediastinum, head and neck, extremities, appendix, and kidneys, with the largest tumours occurring in the abdomen and retroperitoneum.1 Tumours in the retroperitoneal origin with multinodular or ill-defined gross appearance are correlated with a more aggressive clinical behaviour in the form of local recurrence.2 However, the definitive diagnosis of IMTs is seldom made before operation. Surgical resection is the primary treatment for IMT and remains the only therapy that can offer a chance of cure. Here, we report a case of retroperitoneal IMT in a thirteen-year boy in whom the tumour was excised completely with no recurrence. A review of the current literature was also discussed.

Case Report

Our patient was a thirteen years boy with no significant past medial history and initially presented with abdominal distention, anaemia, and poor appetite for one month. Subsequent discussion revealed that the abdominal distension was not associated with nausea, vomiting, or diarrhoea. Physical examination showed a palpable, non-tender mass lesion, measuring 20 cm, in the central and left side of the abdomen.

An ultrasound scan of the abdomen confirmed a large complex mass lesion in the left side of the abdomen, displacing the transverse colon and the small intestines to the right side of abdomen. Chest X-ray did not show any elevation of the diaphragm and active lung lesion.

Complete blood count showed haemoglobin 9.8 g/dL; WBC: 5.17x109/L; HCT: 28.60%; platelet: 838x109/L; red cell indices were hypochromic microcytic anaemia. Liver and renal function tests were within normal limits. CA-199, carcinoembryonic antigen (CEA) and Alpha-fetoprotein (AFP) were also normal.

Abdominal computed tomography (CT) scan was subsequently performed. This showed a 25x18x10 cm, well-defined, heterogeneous mass lesion in the retroperitoneum, with no involvement of the inferior vena cava and the aorta. No significant regional lymphoadenopathy was noted (Figure 1).

Figure 1 Abdominal computed tomography scan demonstrated a well-defined, heterogeneous mass lesion in the left side of the abdomen. Large solid tumour mass measuring 24x17x10 cm in size, we cut sagittalis, showed grayish white and firm internal appearance. (HE x 100)

The patient underwent exploratory laparotomy. Intraoperatively, a large solid mass was identified in the retroperitoneum. Although the tumour was adherent to the left colon, stomach and pancreatic tail, no invasion was noted. Frozen section of the tumour showed spindle-shaped myofibroblast cells, pointing to a probable diagnosis of IMT. Because of this pathologic report (IMT) and the likelihood of local recurrence, part of left colon, stomach and tail of pancreas were also excised together with the tumour. The child recovered well with no post-operative complication. At 12 months after surgery, he remained disease free.


The pathological specimen showed a 24x17x10 cm tumour weighing 3.113 kg (Figure 2). Microscopically, tumour was composed of spindle-shaped myofibroblast cells, scanty giant cells, and many inflammatory cells embraced within collagen abundant and thin-wall blood-abundant vessel stroma. Few focal cells with mitoses were noted.

Figure 2 The removed specimen measures 24 cmx17 cmx10 cm in size. It weights 3.113 kg

Immunohistochemical staining revealed diffuse vimentin positivity with smooth muscle actin in the spindled population (Figure 3). The plump rounded cells showed positivity for desmin. The finial histological diagnosis was an IMT of the retroperitoneal invading stomach, left colon and pancreatic tail with clear resection margins.

Figure 3 Histological section of tumor showing spindle-shaped myofibroblastic cells, scanty giant cells, and many inflammatory cells embraced within collagen abundant and thin-wall blood-abundant vessels stroma. Immunohistochemical staining revealed diffuse smooth muscle actin positivity in the spindled population. (EnVision x 100)


Inflammatory myofibroblastic tumour was first described by Brunn in 1939.3 It has subsequently been reported to occur in a wide variety of anatomic sites. IMT is now thought to be a true neoplasm, but one that shows a wide spectrum of biological behaviour, varying from common benign lesions to the uncommon varieties that are multifocal with high risk of multiple recurrences.4 The most frequent site of occurrence is in the lungs.5 For extra-pulmonary IMTs, small bowel mesentery is the most common site of origin.6 Retroperitoneal locations are exceedingly rare. Indeed, Medline search revealed only six cases. We summarised these published papers in the Table 1.2,7-11

Table 1 The recently case reports of inflammatory myofibroblastic tumour retroperitoneal in the Medline
Reference Sex/Age (year) Location Surgery Size Pathology Follow-up Chemotherapy
Koirala et al, 20107 M/52 Pelvic Removal 12.5 cm IMT 1 year No
Frigui et al, 20098 F/14 Left kidney, retroperitoneal Removal 8 cm IMT NA No
Sugimoto et al, 20089 M/61 Right kidney Removal 3 cm IMT 3 months No
Attili et al, 20052 F/46 Left kidney, retroperitoneal Removal 16 cm IMT 1 year No
Tambo et al, 200310 F/46 Right kidney Mass with right kidney NA IMT 9 months NA
Esmer-Sanchez et al, 200211 F/55 Attach pancrease Removal NA IMT NA NA

NA: Not available; No: Not chemotherapy.
Removal: surgical resection, well-defined margin.

Currently, it is generally accepted that IMT is indeed a true neoplasm. However, the aetiology of IMT has not yet been clarified. The proposed aetiologies included Epstein Barr virus (EBV), Human herpes virus (HHV8), and over expression of interleukin IL-6. Moreover the recent research suggest that IMT is probably a neoplasm rather than a post-inflammatory process because of cytogenetic clonality, recurrent involvement of chromosomal region 2p23, occasional aggressive local behaviour and metastasis of the tumour.12 From the recently report, we know the anaplastic lymphoma kinase (ALK) constitutive activation expressed in the IMT and squamous cell carcinomas.13 This finding has focused intense interest in inhibiting ALK signaling as an effective molecular therapy against disease with ALK-driven pathways. Butrynski14 also report that rearrangement correlates well with ALK expression and kinase domain activation, both of which probably predict ALK dependence and crizotinib sensitivity. The dependence of ALK-rearranged tumours on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumour. However, it is not possible to predict which tumours will have ALK rearrangement or ALK aneuploidy.

IMTs are seldom diagnosed before operation. Making a correct clinical diagnosis of IMT can be difficult because patients present such diverse symptoms. There are several differential diagnoses of a large retroperitoneal mass including germ cell tumour, rhabdomyosarcoma, neuroblastoma (NB) or neuroganglioblastoma. computed tomography (CT) remains a useful, commonly used modality for the evaluation of retroperitoneal mass. It can demonstrate calcification in almost 85% of NB and IMT. MRI is extremely useful in detecting intraspinal tumour extension.15 Positron emission tomography/computed tomography (PET/CT) can help surgeon to precisely locate the tumour, IMT is well known for tendency of local recurrence following resection and tumour metastases. On the basis of imaging findings alone, IMT are difficult to differentiate from other retroperitoneal mass, percutaneous needle biopsy can improve our understanding of the disease decision. On the other hand, NB patients excrete vanillylmandelic acid (VMA) which may point to the diagnosis of NB.

Clinical presentation of intra-abdominal IMT depends on its location and growth pattern. In general, the most common initial symptoms and signs are palpable mass, abdominal distention, weight loss, anaemia, and fever. Intraabdominal tumours usually present with an abdominal mass with features of inflammation, such as fever, weight loss and anaemia. Haematologically, there was hypochromic microcytic anaemia in this case.

Typically, IMT is characterised by the expression of vimentin, smooth muscle actin, and cytokeratins, corresponding to that of myofibroblasts along with other inflammatory markers (CD-68 is an inflammatory marker) (Figure 4).16 In the present case, Immunohistochemical staining revealed positive for smooth muscle actin and desmin, which are smooth muscle markers and CD-68 is an inflammatory marker, suggesting the tumour to be IMT. Based on the pathological patterns, extra-pulmonary IMTs are histologically categorised into three types:17 (1) resemble granulation tissue, nodular fasciitis; (2) resemble fibromatosis, fibrous histocytoma, and smooth muscle neoplasm; (3) resemble a scar or desmoids fibromatosis. These are three different pathologic types of IMT. Based on the above features, we can diagnosis IMT and differentiate from other tumours.

Figure 4 Immunohistochemical staining, the CD-68(inflammatory marker) showed the focal positivity in the tumour. (EnVision x 100).

Surgical resection remains the best method of cure. Adjuvant chemotherapy or radiotherapy has been proved to have no or little benefit.18 Risk of recurrence has been reported to be associated with larger tumours (>8 cm), tumours which originated from the omentum with ill-defined margin, or those presented with pathologically atypia, ganglionlike cells. Thus, close follow-up after primary surgery is necessary.19

In conclusion, IMT is neoplasm of proliferating myofibroblasts with an associated inflammatory component. Though IMT is uncommon, it should be kept as one of differential diagnosis of retroperitoneal masses. Final diagnosis is based on histological features and immunohistochemical staining. Complete surgical excision should be the aim of curative treatment. Long-term clinical and imaging follow-up are indicated because of the possibility of local recurrence even after many years.


1. Hojo H, Newton WA, Hamoudi AB, et al. Pseudosarcomatous myofibroblastic tumor of the urinary bladder in children: a study of 11 cases with review of the literature. An Intergroup Rhabdomyosarcoma study. Am J Surg Pathol 1995;19:1224-36.

2. Attili SV, Chandra CR, Hemant DK, Bapsy PP, RamaRao C, Anupama G. Retroperitoneal Inflammatory Myofibroblastic Tumor. World J Surg Oncol 2005;3:66.

3. Brunn H. Two interesting benign lung tumors of contradictory histopathology. J Thorac Surg 1939; 9:119-31.

4. Karnak I, Senocak ME, Ciftci AO, et al. Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg 2001;36:908-12.

5. Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumors. Pathology and Genetics of tumors of soft tissue and bone; Vol 2 Fibroblastic/Myofibroblastic tumors. Lyon: IARC Press, 2002:91-3.

6. Apa H, Diniz G, Saritas T, et al. Abdominal inflammatory myofibroblastic tumor: review of the literature by means of a case report. Turkish J Cancer 2002;32:28-31.

7. Koirala R, Shakya VC, Agrawal CS, et al. Retroperitoneal inflammatory myofibroblastic tumor. Am J Surg 2010;199:e17-9.

8. Frigui M, Khabir A, Jallouli M, et al. Recurrent inflammatory myofibroblastic tumor with renal, retroperitoneal and lymph node involvement. Rev Med Interne 2009;30:372-6.

9. Sugimoto T, Miwa S, Sugata T, Zen Y. A case of inflammatory myofibroblastic tumor recognized in the retroperitoneum and the kidney. Hinyokika Kiyo 2008;54:5-7.

10. Tambo M, Kondo H, Kitadchi T, et al. A case of inflammatory myofibroblastic tumor of the retroperitoneum. Hinyokika Kiyo 2003;49:273-6. Japanese.

11. Esmer-Sanchez D, Rangel D. Inflammatory pseudotumor of the retroperitoneum. Rev Gastroenterol Mex 2002;67:97-9.

12. Kapusta LR, Weiss MA, Ramsay J, Lopez-Beltran A, Srigley JR. Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol 2003;27:658-66.

13. Mosse YP, Wood A, Maris JM. Inhibition of ALK Signaling for cancer therapy. Clin Cancer Res 2009;15:5609-14.

14. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.

15. Kim SJ, Kim WS, Cheon JE, et al. Tumors of the Abdomen as Mimickers of Malignancy: Imaging Features in Nine Children. AJR 2009;193:1419-24.

16. Czauderna P, Schaarschmidt K, Komasara L, et al. Abdominal inflammatory masses mimicking neoplasia in children: experience of two centers. Pediatr Surg Int 2005;21:346-50.

17. Zuccarello C, Arena F, Fazzari C, Arena S, Nicotina PA. Small bowel intussusception by local recurrence of an inflammatory myofibroblastic tumor: report of a case and review of the literature. Minerva Pediatr 2006;58:495-8.

18. Dishop MK, Warner BW, Dehner LP, et al. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy. J Pediatr Hematol Oncol 2003;25:153-8.

19. Hoseok I, Joungho H, Ahn KM, Lee SI, Jhingook K. Complete surgical resection of inflammatory myofibroblastic tumor with carinal reconstruction in a 4-year-old boy. J Pediatr Surg 2005;40:e23-5.


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2023 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.